

Cover Story
Clinical
Imatinib—the pathbreaking cancer drug that gave Philadelphia chromosome-positive chronic myeloid leukemia patients near-normal life expectancies—now stands poised to save even more lives.
Health Equity
By Matthew Bin Han Ong
In Brief


Clinical Roundup


Drugs & Targets
NCI Trials


NCI Trials for November 2023
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration”
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- George Sigounas named the first-ever chief science advisor at NCI
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Makary: Level of evidence is an artificial and dogmatic construct
- Reimagining cancer care for a new generation of patients